RevenanasBook a free audit

M&A

AstraZeneca reportedly offers ~$10B to acquire Rhythm Pharmaceuticals; analysts see bidding war

Biotech

M&A

Key Facts

Signal Type

M&A

Industry

Biotech

Companies

AstraZeneca, Rhythm Pharmaceuticals, Jefferies, Leerink Partners, William Blair

Date

What Happened

AstraZeneca has reportedly offered roughly $10 billion to acquire Rhythm Pharmaceuticals, a Boston-based biopharma commercializing Imcivree, a first-in-class weight-loss medicine for rare genetic conditions and hypothalamic obesity. The Wall Street Journal reported the initial bid at $124 per share, with potential milestones raising the total to $134 per share. Neither company has publicly commented.

Who Is Affected

Rhythm Pharmaceuticals is the direct target, but the ripple effect extends to every large-cap biopharma with a metabolic business. Analysts at William Blair note that any biopharma company with a metabolic portfolio could be a potential bidder, making this a sector-wide trigger. Rhythm's management is particularly focused on the value of its Prader-Willi syndrome program, which analysts say is not fully reflected in the current offer.

Market Impact

The proposed acquisition has immediate implications for the obesity and rare disease drug market. Key analyst views:

  • Jefferies: The offer assigns “minimal valuation” to Rhythm’s Prader-Willi syndrome program; deal unlikely unless that value is recognized.
  • Leerink Partners: Price tag is “broadly fair” but expects negotiations for higher milestone payments or competing bids.
  • William Blair: Predicts a bidding war given Rhythm’s “incredibly valuable asset” and assigns a discounted cash flow valuation of $166 per share.

Analysts forecast over $2 billion in peak sales from Imcivree’s hypothalamic obesity indication alone, further intensifying strategic interest.

What to Watch

Watch for competing bids from other large-cap biopharmas, particularly those with metabolic disease franchises, and for Rhythm’s public response to the offer. The outcome of the Prader-Willi syndrome program’s value negotiation will be critical. Also monitor AstraZeneca’s restructuring and $1.5B cost-saving plan for clues on integration priorities. SDRs should track Rhythm’s hiring, vendor contracts, and regulatory timelines for sales triggers in clinical trial and M&A software.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner